MedTrace Logo

Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

NCT05729646 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2023-07-25

No results posted yet for this study

Summary

This study is a prospective, multi-center, randomized controlled phase II trial to compare the efficacy of perioperative SOX plus toripalimab, toripalimab monotherapy with SOX regimen in participants with dMMR locally advanced gastric or esophagogastric junction adenocarcinoma

Conditions

  • Adenocarcinoma of the Stomach
  • Adenocarcinoma of Esophagogastric Junction
  • Mismatch Repair Deficiency

Interventions

DRUG

Toripalimab

Perioperative Toripalimab, 240 mg IV infusion

DRUG

Oxaliplatin

Oxaliplatin (130 mg/m2) infusion as perioperative chemotherapy

DRUG

S1

S-1 orally intake as perioperative chemotherapy

Sponsors & Collaborators

  • Yu jiren

    lead OTHER

Principal Investigators

  • Jiren Yu · First Affiliated Hospital of Zhejiang University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-31
Primary Completion
2026-02-28
Completion
2029-02-28

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05729646 on ClinicalTrials.gov